| http://www.w3.org/ns/prov#value | - This study is also enrolling patients with other types of cancers.This is a Phase I trialwhat is involved:Participants will receive:DEC-205-NY-ESO-1 fusion protein vaccine on days 1, 29, 57, and 113with or without:Sirolimus by mouthAdditional procedures:Please contact research siteTrial length:About 5 monthsPost-trial follow-up:Please contact research siteSponsor:OtherMore informationView eligibili
|
